Suppr超能文献

相似文献

1
Antileishmanial structure-activity relationships of synthetic phospholipids: in vitro and in vivo activities of selected derivatives.
Antimicrob Agents Chemother. 2007 Dec;51(12):4525-8. doi: 10.1128/AAC.00465-07. Epub 2007 Oct 1.
2
Syntheses of new substituted triazino tetrahydroisoquinolines and beta-carbolines as novel antileishmanial agents.
Eur J Med Chem. 2006 Jan;41(1):106-13. doi: 10.1016/j.ejmech.2005.09.007. Epub 2005 Dec 13.
3
Synthesis and antileishmanial activity of C7- and C12-functionalized dehydroabietylamine derivatives.
Eur J Med Chem. 2016 Oct 4;121:445-450. doi: 10.1016/j.ejmech.2016.06.004. Epub 2016 Jun 6.
4
Antileishmanial ring-substituted ether phospholipids.
J Med Chem. 2003 Feb 27;46(5):755-67. doi: 10.1021/jm020972c.
5
Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolines as antileishmanial agents.
Eur J Med Chem. 2010 Aug;45(8):3274-80. doi: 10.1016/j.ejmech.2010.04.004. Epub 2010 Apr 14.
6
Synthesis and in vitro antileishmanial activity of 5-substituted-2'-deoxyuridine derivatives.
Bioorg Chem. 2005 Dec;33(6):439-47. doi: 10.1016/j.bioorg.2005.07.001. Epub 2005 Sep 15.
7
Antileishmanial ferrocenylquinoline derivatives: Synthesis and biological evaluation against Leishmania donovani.
Eur J Med Chem. 2016 Nov 29;124:468-479. doi: 10.1016/j.ejmech.2016.08.049. Epub 2016 Aug 24.
8
Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.
Eur J Med Chem. 2015 Mar 6;92:282-94. doi: 10.1016/j.ejmech.2014.12.056. Epub 2014 Dec 31.
9
Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents.
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5474-7. doi: 10.1016/j.bmcl.2009.07.081. Epub 2009 Jul 19.
10
Synthesis and biological evaluation of 2-arylbenzimidazoles targeting Leishmania donovani.
Bioorg Med Chem Lett. 2015 May 1;25(9):1933-7. doi: 10.1016/j.bmcl.2015.03.027. Epub 2015 Mar 18.

引用本文的文献

2
Synthesis and antifungal activities of miltefosine analogs.
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4828-31. doi: 10.1016/j.bmcl.2013.06.096. Epub 2013 Jul 6.

本文引用的文献

1
3D-Quantitative structure-activity relationships of synthetic antileishmanial ring-substituted ether phospholipids.
Bioorg Med Chem. 2007 Feb 1;15(3):1252-65. doi: 10.1016/j.bmc.2006.11.018. Epub 2006 Nov 14.
2
Development of miltefosine as an oral treatment for leishmaniasis.
Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20. doi: 10.1016/j.trstmh.2006.02.010. Epub 2006 May 26.
4
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
Lancet Infect Dis. 2005 Dec;5(12):763-74. doi: 10.1016/S1473-3099(05)70296-6.
5
Leishmaniasis.
Nat Rev Microbiol. 2004 Sep;2(9):692. doi: 10.1038/nrmicro981.
6
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
Int J Antimicrob Agents. 2003 Oct;22(4):380-7. doi: 10.1016/s0924-8579(03)00125-0.
7
Antiprotozoal activities of phospholipid analogues.
Mol Biochem Parasitol. 2003 Feb;126(2):165-72. doi: 10.1016/s0166-6851(02)00283-9.
8
Antileishmanial ring-substituted ether phospholipids.
J Med Chem. 2003 Feb 27;46(5):755-67. doi: 10.1021/jm020972c.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验